KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in chemotherapy (chemo)–naive patients with metastatic castration-resistant prostate cancer (mCRPC)
Todenhöfer, T., Piulats, J.M., Ferrario, C., Linch, M.D., Stoeckle, M., Laguerre, B., Arranz, J.A., Fong, P.C.C., Berry, W.R., Emmenegger, U., Mourey, L., Mar, N., Appleman, L.J., Joshua, A.M., Conter, H.J., Li, X.T., Schloss, C., Poehlein, C.H., De Bono, J.S., Yu, E.Y.
Published in European urology (01.02.2022)
Published in European urology (01.02.2022)
Get full text
Journal Article
217O Pembrolizumab (pembro) combination therapies in patients with metastatic castration-resistant prostate cancer (mCRPC): Cohorts A-C of the phase Ib/II KEYNOTE-365 study
Joshua, A.M., Gurney, H., Retz, M., Tafreshi, A., Fong, P.C.C., Shore, N.D., Romano, E., Augustin, M., Piulats, J.M., Berry, W.R., Kolinsky, M.P., Sridhar, S.S., Conter, H.J., Todenhöfer, T., Appleman, L.J., Wu, H., Schloss, C., Poehlein, C.H., de Bono, J.S., Yu, E.Y.
Published in Annals of oncology (01.11.2020)
Published in Annals of oncology (01.11.2020)
Get full text
Journal Article
612P Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients
Yu, E., Piulats, J.M., Gravis, G., Fong, P.C.C., Todenhöfer, T., Laguerre, B., Arranz Arija, J.A., Oudard, S., Massard, C., Stoeckle, M., Nordquist, L.T., Carles, J., Kolinsky, M.P., Augustin, M., Gurney, H., Tafreshi, A., Li, X.T., Poehlein, C.H., Schloss, C., de Bono, J.S.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline BRCA mutation on efficacy
Coleman, R.L., Oza, A.M., Lorusso, D., Aghajanian, C.A., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Gancedo, M. Amenedo, Fong, P.C.C., Goh, J.C., O'Malley, D.M., Banerjee, S., Goble, S., Cameron, T., Ledermann, J.A.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article
Post hoc exploratory analysis of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma from the randomized, placebo-controlled phase III study ARIEL3: Effect of a deleterious germline or no germline mutation on efficacy
Coleman, R.L., Oza, A.M., Lorusso, D., Aghajanian, C.A., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Gancedo, M. Amenedo, Fong, P.C.C., Goh, J.C., O'Malley, D.M., Banerjee, S., Goble, S., Cameron, T., Ledermann, J.A.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article
The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma
Ledermann, J.A., Oza, A.M., Lorusso, D., Aghajanian, C.A., Oaknin, A., Dean, A., Colombo, N., Weberpals, J.I., Clamp, A.R., Scambia, G., Leary, A., Holloway, R.W., Gancedo, M. Amenedo, Fong, P.C.C., Goh, J.C., Backes, F.J., Banerjee, S., Goble, S., Cameron, T., Coleman, R.L.
Published in Gynecologic oncology (01.06.2019)
Published in Gynecologic oncology (01.06.2019)
Get full text
Journal Article